Myriad Genetics Inc. (MYGN)

Business: Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally.

IPO Date: 05-Oct-1995

CEO, Pres & Director: Mr. Paul J. Diaz

Exec. VP, CFO & Treasurer: Mr. R. Bryan Riggsbee

Listing: NASDAQ: MYGN

Country: United States

Headquarters: Salt Lake City, UT

Website: https://myriad.com

Market cap: $2,230.20 Mln

Revenue (TTM): $682.40 Mln

Earnings (TTM): $-8.20 Mln

Cash: $268.40 Mln

Total Debt: $89.90 Mln

Insider's Holding: 2.10%

Liquidity: Low

52 Week range: $16.02 - 36.95

Shares outstanding: 80,343,200

10 Years Aggregate:

• CFO: $982.58 Mln
• EBITDA: $1,066.55 Mln
• Net Profit: $406.66 Mln